SciSparc’s Neurothera Labs announces publication of international patent

SciSparc (SPRC) announced that NeuroThera Labs, in which SciSparc holds a controlling interest of approximately 75%, has advanced its collaboration with Clearmind Medicine (CMND) with the publication of an international patent application under the Patent Cooperation Treaty for a novel combination therapy aimed at treating weight loss and metabolic dysfunction-associated steatotic liver disease. The patent publication highlights the potential of a 5-methoxy-2-aminoindane-Palmitoylethanolamide combination to offer a safe, non-hallucinogenic neuroplastogen treatment for two major global health challenges: obesity, affecting over 890 million adults worldwide, and MASLD, impacting approximately 30% of the global adult population. Moreover, due to the presumed mechanism of action of the combination, this therapeutic option may offer a safer, easier and more cost effective option than GLP-1s agonists for obesity and MASLD. By combining Clearmind’s MEAI platform with NeuroThera’s PEA, the companies wish to address the escalating demand for effective, tolerable and safe treatments in the obesity and liver health space.